Standalone Lab-on-a-Chip Systems toward the Evaluation
of Therapeutic Biomaterials in Individualized Disease Treatment
- Publication date
- Publisher
Abstract
As
each tumor is unique, treatments should be individualized in
terms of their drug formulation and time dependent dosing. In vitro
lab-on-a-chip (LOC) drug testing is a viable avenue to individualize
treatments. A drug testing platform in the form of a customizable
standalone LOC system is proposed for treatment individualization
in vitro. The platform was used to individualize the treatment of
pancreatic cancer by using PANC-1 and MIA PaCa-2 cell lines cultured
on-chip. Using on-chip drug uptake, growth, and migration inhibition
assays, the therapeutic effect of various treatment combinations was
analyzed. Thereafter, optimized treatments were devised for each cell
line. The individualized dosage for MIA PaCa-2 cell line was found
to be between 0.05–0.1 μg/μL of doxorubicin (DOX),
where the greatest growth and migration inhibition effects were observed.
As the PANC-1 cell line showed resistance to DOX only formulations,
a multidrug approach was used for individualized treatment. Compared
to the DOX only formulations, the individualized treatment produced
the same degree of migration inhibition but with 5–10 times
lower concentration of DOX, potentially minimizing the side-effects
of the treatment. Furthermore, the individualized treatment had an
average of 672.4% higher rate of growth inhibition. Finally, a preliminary
study showed how a tested formulation from the LOC system can be translated
for use by employing a nanoparticle system for controlled delivery,
producing similar therapeutic effects. The use of such systems in
clinical practice could potentially revolutionize treatment formulation
by maximizing the therapeutic effects of existing treatments while
minimizing their potential side effects through individualization
of treatment